Will investments in biobanks, prospective cohorts, and markers of common patterns of variation benefit other populations for drug response and disease susceptibility gene discovery?

Morris W. Foster; R. R. Sharp

doi:10.1038/sj.tpj.6500295

Will investments in biobanks, prospective cohorts, and markers of common patterns of variation benefit other populations for drug response and disease susceptibility gene discovery?

Morris W. Foster, R. R. Sharp

Quantitative Health Sciences

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Original language	English (US)
Pages (from-to)	75-80
Number of pages	6
Journal	Pharmacogenomics Journal
Volume	5
Issue number	2
DOIs	https://doi.org/10.1038/sj.tpj.6500295
State	Published - 2005

ASJC Scopus subject areas

Molecular Medicine
Genetics
Pharmacology

Access to Document

10.1038/sj.tpj.6500295

Cite this

@article{48c01c7865fb47d79f8767d2630994c9,

title = "Will investments in biobanks, prospective cohorts, and markers of common patterns of variation benefit other populations for drug response and disease susceptibility gene discovery?",

author = "Foster, {Morris W.} and Sharp, {R. R.}",

note = "Funding Information: This publication was made possible by grant numbers ES11174 from the National Institute on Environmental Health Sciences and HG02691 the National Human Genome Research Institute. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIEHS, NHGRI, or the National Institutes of Health. We also are grateful for comments made by LD Brooks and an anonymous reviewer on earlier versions.",

year = "2005",

doi = "10.1038/sj.tpj.6500295",

language = "English (US)",

volume = "5",

pages = "75--80",

journal = "Pharmacogenomics Journal",

issn = "1470-269X",